Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Schmid, Gabriel ^a   Notaro, Sara ^a,b   Reimer, Daniel ^a   Abdel Azim, Samira ^a   Duggan Peer, Michaela ^a   Holly, Jessica ^a   Fiegl, Heidi ^a   Rössler, Julia ^a   Wiedemair, Annemarie ^a   Concin, Nicole ^a   Altevogt, Peter ^c,d   Marth, Christian ^a   Zeimet, Alain Gustave ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF BRESCIA   (Italy)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Epigenetics; Gene silencing; MiR 34a; Ovarian cancer; Promotor hypermethylation

Indexed keywords

MICRORNA; MIRN34 MICRORNA, HUMAN;

AGED; CHEMISTRY; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; METABOLISM; MIDDLE AGED; MORTALITY; OVARY; OVARY TUMOR; PROMOTER REGION; SURVIVAL ANALYSIS; TISSUE MICROARRAY;

AGED; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MICRORNAS; MIDDLE AGED; OVARIAN NEOPLASMS; OVARY; PROMOTER REGIONS, GENETIC; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS;

EID: 84957946146     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2135-2     Document Type: Article

References (24)

1. Shih Ie M, Kurman RJ. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res. 2005;11:7273-9.
2. Kurman RJ et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res. 2009;69(9):4036-42.
3. Shih Ie M. Kurman RJ. Ovarian Tumorigenesis. 2004;164:1511-8.
4. Markman M. Pharmaceutical management of ovarian cancer: current status. Drugs. 2008;68:771-89.
5. Lawrie CH. MicroRNAs and lymphomagenesis: a functional review. Br J Haematol. 2013;160:571-81.
6. Esquela-Kerscher A, Slack FJ. Oncomirs - microsRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259-69.
7. Bommer GT, Gerin I, Feng Y, Feng Y. p53 mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. 2007;17:1298-307.
8. Chang TC, Wentzel EA, Kent OA. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007;26:745-52.
9. Kumar B, Yadav A, Lang J, Teknos TN, Kumar P. Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis. 2012.
10. Liu C et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011;17(2):211-5.
11. Wicha MS. Stemming a tumor with a little miR. Nat Med. 2011;17:162-4.
12. Reimer D, Hubalek M, Kiefel H, Riedle S, Skvortsov S, Erdel M, et al. Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer. Oncogene. 2011;30:4038-49.
13. Schirmer U, Doberstein K, Rupp AK, Bretz NP, Wuttig D, Kiefel H, Breunig C, Fiegl H, Müller-Holzner E, Zeillinger R, Schuster E, Zeimet AG, Sültmann H, Altevogt P. Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. Oncotarget. 2014;5(2):462-72.
14. Reimer D, Sadr S, Wiedemair A, Stadlmann S, Concin N, Hofstetter G. Clinical relevance of E2F family members in ovarian cancer-an evaluation in a training set of 77 patients. Clin Cancer Res. 2007;13:144-51.
15. Takai D, Jones PA. The CpG island searcher: a new WWW resource. In Silico Biol. 2003;3:235-40.
16. Reimer D, Hubalek M, Riedle S, Skvortsov S, Erdel M, Concin N, Fiegl H, Müller-Holzner E, Marth C, Illmensee K, Altevogt P, Zeimet AG. E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancer. Cancer Res. 2010;70(11):4613-23.
17. Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Abel-Azim S, Müller-Holzner E, Ben-Arie A, van Kempen LC, Petru E, Jahn S, Geels YP, Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, Bulten J, Meuter A, Tanouye S, Oppelt P, Stroh-Weigert M, Reinthaller A, Mariani A, Hackl W, Netzer M, Schirmer U, Vergote I, Altevogt P, Marth C, Fogel M. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst. 2013;7(105(15)):1142-50.
18. Bondong S, Kiefel H, Hielscher T, Zeimet AG, Zeillinger R, Pils D, Schuster E, Castillo-Tong DC, Cadron I, Vergote I, Braicu I, Sehouli J, Mahner S, Fogel M, Altevogt P. Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-ΚB activation. Ann Oncol. 2012;23(7):1795-802.
19. Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene. 2007;26:5017-22.
20. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle. 2007;6:1586-93.
21. Zeimet AG, Marth C. Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol. 2003;4(7):415-22.
22. Wei B, Huang QY, Huang SR, Mai W, Zhong XG. MicroRNA 34a attenuates the proliferation, invasion and metastasis of gastric cancer cells via downregulation of MET. Mol Med Rep. 2015;12(4):5255-61.
23. Li RSX, Ling F, Wang C, Liu J, Wang W, Li M. MiR-34a suppresses ovarian cancer proliferation and motility by targeting AXL. Tumour Biol. 2015;36(9):7277-83.
24. Vogt M, Munding J, Grüner M, Liffers ST, Verdoodt B, Hauk J, Steinstraesser L, Tannapfel A, 26 Hermeking H. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch. 2011;458(3):313-22.